ATE232732T1 - 2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen - Google Patents

2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen

Info

Publication number
ATE232732T1
ATE232732T1 AT95929637T AT95929637T ATE232732T1 AT E232732 T1 ATE232732 T1 AT E232732T1 AT 95929637 T AT95929637 T AT 95929637T AT 95929637 T AT95929637 T AT 95929637T AT E232732 T1 ATE232732 T1 AT E232732T1
Authority
AT
Austria
Prior art keywords
phosphorthioate
oligoadenylate
phosphodiester
antiviral
antiviral uses
Prior art date
Application number
AT95929637T
Other languages
English (en)
Inventor
Robert F Suhadolnik
Wolfgang Pfleiderer
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Application granted granted Critical
Publication of ATE232732T1 publication Critical patent/ATE232732T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT95929637T 1994-09-14 1995-08-22 2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen ATE232732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30627394A 1994-09-14 1994-09-14
PCT/US1995/010683 WO1996008256A1 (en) 1994-09-14 1995-08-22 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof

Publications (1)

Publication Number Publication Date
ATE232732T1 true ATE232732T1 (de) 2003-03-15

Family

ID=23184567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929637T ATE232732T1 (de) 1994-09-14 1995-08-22 2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen

Country Status (10)

Country Link
US (1) US5863905A (de)
EP (1) EP0777485B1 (de)
JP (2) JP3142574B2 (de)
AT (1) ATE232732T1 (de)
AU (1) AU686005B2 (de)
CA (1) CA2199747C (de)
DE (1) DE69529680T2 (de)
ES (1) ES2188667T3 (de)
NZ (1) NZ291713A (de)
WO (1) WO1996008256A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5587514A (en) * 1993-11-08 1996-12-24 Emory University Diastereoselective synthesis of hydroxyethylene dipeptide isosteres
WO1998056384A1 (en) 1997-06-12 1998-12-17 Temple University - Of The Commonwealth System Of Higher Education Aminoaklanoyl-linked conjugates of 2',5'-oligoadenylate and antiviral uses thereof
WO1998056385A1 (en) 1997-06-12 1998-12-17 Temple University - Of The Commonwealth System Of Higher Education Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
US7057062B2 (en) * 2002-04-11 2006-06-06 Isis Pharmaceuticals, Inc. Process for manufacturing purified phosphorodiamidite
US7034177B2 (en) * 2002-06-13 2006-04-25 Rhodia Inc Process of making phosphordiamidite compounds
AU2003208084A1 (en) * 2002-07-30 2004-02-16 Sankyo Co., Ltd Phosmidosine derivative and process for producing the same
EP3366772A1 (de) 2013-02-22 2018-08-29 Sirna Therapeutics, Inc. Moleküle von kurzer eingreifender nukleinsäure (sina) mit einer 2'-internukleosid-verbindung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US4464359A (en) * 1981-04-10 1984-08-07 Research Corporation (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
GB2136435A (en) * 1983-03-10 1984-09-19 Julian Gordon Specific anti-oligo (a) antibodies
US4824941A (en) * 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4859768A (en) * 1984-07-11 1989-08-22 Temple University Of The Commonwealth System Of Higher Education Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
IL76233A (en) * 1985-08-28 1994-05-30 Yeda Res & Dev DNA molecules coding for an enyzme having (2'-5') oligo a synthetase activity, expression vectors comprising them, microorganisms transfected by thevectors, and amino acid sequences corresponding to the DNA molecules
DE3683335D1 (de) * 1985-08-28 1992-02-20 Yeda Res & Dev Interferon-induziertes (2'-5')-oligo-a-synthetase-gen, mrna, cdna und enzyme mit (2'-5')-oligo-a-synthetase-aktivitaet.
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides

Also Published As

Publication number Publication date
AU686005B2 (en) 1998-01-29
DE69529680T2 (de) 2003-08-14
EP0777485B1 (de) 2003-02-19
ES2188667T3 (es) 2003-07-01
EP0777485A4 (de) 1998-12-02
JPH10502666A (ja) 1998-03-10
JP3142574B2 (ja) 2001-03-07
EP0777485A1 (de) 1997-06-11
AU3332995A (en) 1996-03-29
US5863905A (en) 1999-01-26
DE69529680D1 (de) 2003-03-27
NZ291713A (en) 1998-01-26
WO1996008256A1 (en) 1996-03-21
CA2199747A1 (en) 1996-03-21
CA2199747C (en) 2003-05-27
JP2001172185A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
ES2067813T3 (es) Derivados substituidos de valinamida.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
DE59407626D1 (de) Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
TR199901305T2 (xx) Calpain-�nleyicileri olarak ketonbenzamidler
BG106390A (en) Novel spiro compounds
IS4425A (is) Arylþíósambönd sem varnarefni gegn bakteríum og veirum
CA2276455A1 (en) Phthalazinones
TR199901282T2 (xx) Heterosiklik olarak ikame edilmi� yeni benzamitler.
ES8207169A1 (es) Un procedimiento para la preparacion de nuevos derivados de piperazinilquinazolina y de homopiperazinilquinazolina hi- pertensora con acticidad.
EE04312B1 (et) Dihüdrobensofuraanid, nende kasutamine ravimite valmistamiseks ning neid sisaldavad ravimid
DE3585980D1 (de) Hydrazinderivate und ihre verwendung.
KR910700089A (ko) 히드로클로로플루오로프로판의 공비 조성물 또는 공비형 조성물
ATE232732T1 (de) 2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen
FI851261L (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
HK48590A (en) NOVEL 8α-ACYLAMINOERGOLINES
YU48326B (sh) Fungicidi
DE3561153D1 (de) Benzoylurea derivatives
TW333526B (en) Pesticidal 1-arylpyrazoles
ES2072304T3 (es) Pirazolinas n-sulfeniladas y n-aciladas.
ES2052509T3 (es) 2-oxo-1-(fosforo sustituido)-azetidinas.
ATE165089T1 (de) Thiocarbamoylverbindungen als mikrobizide
TR199800958A2 (xx) Herbisidal 3,5-Difloropridinleri.
ATE127806T1 (de) Antibiotikverbindungen und ihre herstellung.
DK181089D0 (da) 1-dimethylcarbamoyl-3-substituerede-5-substituerede-1h-1,2,4-triazoler
ATE263560T1 (de) Neue verwendung von citreamicinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties